Investors Get Second Shot at Baxter Class Action
Dealing a blow to defense counsel at Skadden, the court resurrected shareholder derivative claims that Baxter's board cost the company at least $550 million by failing to address chronic problems with its Colleague line of infusion pumps.
This premium content is reserved for American Lawyer subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now